2023년 이식분야 Top Articles
페이지 정보
작성자 신호식 작성일23-12-30 11:31 조회269회 댓글0건관련링크
https://www.multibriefs.com/briefs/ast/ast122923.php
본문
https://www.multibriefs.com/briefs/ast/ast122923.php
| Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients From June 23: This study sought to compare the efficacy and safety of letermovir with valganciclovir for prevention of CMV disease in CMV-seronegative kidney transplant recipients who receive an organ from a CMV-seropositive donor. Read More |
| Advertisement |
| First-in-Human Liver Transplantation From a Centenarian Deceased Donor After Brain Death From Oct. 6: Liver transplantation from elderly donors is expanding due to demand for liver grafts, ageing of recipients and donors, and introduction of machine perfusion. The following report is about a liver transplant from a 100-year-old deceased donor after brain death. Read More |
| Increased Volume of Organ Offers and Decreased Efficiency of Kidney Placement Under Circle-Based Kidney Allocation From May 19: The newest kidney allocation policy broadened geographic distribution while increasing allocation system complexity. We studied the volume of kidney offers received by transplant centers and efficiency of kidney placement since KAS250. Read More |
| Advertisement |
| Outcomes of Early vs Late Treatment Initiation in Solid Organ Transplantation From HCV NAT+ Donors to HCV-Uninfected Recipients: Results From the HCV-TARGET Study From Oct. 27: Curative hepatitis C (HCV) therapy has increased transplantation from HCV-infected (NAT+) donors to HCV-uninfected recipients (D+/R-). We evaluated outcomes of early and late HCV-treatment among D+/R- non-liver organ transplants. Read More |
| Racial and Ethnic Disparities in Psychosocial Evaluation and Liver Transplant Waitlisting From June 9: Health disparities have been well-described in all stages of the liver transplantation process. Using data from psychosocial evaluations and the Stanford Integrated Psychosocial Assessment, our objective was to investigate potential racial and ethnic inequities in overall LT waitlisting and not waitlisting for medical or psychosocial reasons. Read More |
| Advertisement |
| Donor-Derived Cell-Free DNA in Kidney Transplant Recipients With Indication Biopsy — Results of a Prospective Single-Center Trial From Nov. 10: Donor-derived cell-free DNA identifies allograft injury and discriminates active rejection from no rejection. In this prospective study, 106 kidney transplant recipients with 108 clinically indicated biopsies were enrolled at Heidelberg University Hospital between November 2020 and December 2022 to validate the clinical value of dd-cfDNA in a cohort of German patients. Read More |
| A Rational Approach To Guide Cost-Effective De Novo Donor-Specific Antibody Surveillance With Tacrolimus Immunosuppression From Aug. 11: De novo DSA after renal transplantation has been shown to correlate with antibody-mediated rejection and allograft loss. However, the lack of proven interventions and the time and cost associated with annual screening for dnDSA are difficult to justify for all recipients. Read More |
| Addressing Sex-Based Disparities in Solid Organ Transplantation in the United States — A Conference Report From April 14: Solid organ transplantation provides the best treatment for end-stage organ failure, but significant sex-based disparities in transplant access exist. On June 25, 2021, a virtual multidisciplinary conference was convened to address sex-based disparities in transplantation. Common themes contributing to sex-based disparities were noted across kidney, liver, heart, and lung transplantation, specifically the existence of barriers to referral and wait listing for women, the pitfalls of using serum creatinine, the issue of donor/recipient size mismatch, approaches to frailty and a higher prevalence of allosensitization among women. Read More |
| Advertisement | |
| Kidney Transplant Tolerance Clinical Trial The FREEDOM-1 Phase 3 clinical trial is evaluating FCR001, an investigational cell therapy with the potential to induce durable immune tolerance without the need for chronic immunosuppression across all levels of HLA mismatch. FREEDOM-1 is now enrolling de novo living donor kidney transplant patients. Learn More | |
| The First 4-Way Liver Paired Exchange from an Interdisciplinary Collaboration between Healthcare Professionals and Design Economists From July 7: We report initial results of a Liver Paired Exchange (LPE) program established at the Liver Transplant Institute at Inonu University through collaboration with design economists. Since June 2022, the program has been using a matching procedure that maximizes the number of living donor liver transplants (LDLTs) to the patients in the pool subject to the ethical framework and the logistical constraints of the program. Read More |
| Advertisement |
| Microvascular Inflammation in the Absence of Human Leukocyte Antigen-Donor-Specific Antibody and C4d: An Orphan Category in Banff Classification With Cytotoxic T and Natural Killer Cell Infiltration From April 28: Isolated microvascular inflammation without HLA donor-specific antibodies or C4d deposition in peritubular capillaries remains an enigmatic phenotype that cannot be categorized as antibody-mediated rejection in recent Banff classifications. Read More |
| Advertisement | |
| Immunosuppression in de novo kidney transplant recipients There are many factors that may put a graft at risk, such as infections, nephrotoxicity, declining adherence, and inadequate immunosuppression. It can be difficult to achieve a balance between overimmunosuppression and underimmunosuppression in kidney transplant patients, putting patients at risk. Read More |
| Comparison of High-Dose IVIG and Rituximab Versus Rituximab as a Preemptive Therapy for De Novo Donor-Specific Antibodies in Kidney Transplant Patients From May 19: De novo donor-specific antibody is associated with a higher risk of kidney graft failure. However, it is unknown whether preemptive treatment of subclinical dnDSA is beneficial. Here, we assessed the efficacy of high-dose intravenous immunoglobulin and rituximab combination therapy for subclinical dnDSA. Read More |
| Advertisement |
| An Experiment on the Impact of Predictive Analytics on Kidney Offer Acceptance Decisions From March 24: Due to the breadth of factors that might affect kidney transplant decisions to accept an organ or wait for another, presumably "better" offer, a high degree of heterogeneity in decision-making exists among transplant surgeons and hospitals. These decisions do not typically include objective predictions regarding the future availability of equivalent or better-quality organs, nor the likelihood of patient death while waiting for another organ. Read More |
| Advertisement | |
| The Leading dd-cfDNA Test in Transplant AlloSure is the only dd-cfDNA test validated for long-term transplant surveillance. Learn More | |
| TNX-1500, an Fc-modified Anti-CD154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival From April 7: Blockade of the CD40/CD154 T cell costimulation pathway is a promising approach to supplement or replace current clinical immunosuppression in solid organ transplantation. We evaluated the tolerability and activity of a novel humanized anti-CD154 monoclonal antibody, TNX-1500 in a nonhuman primate heterotopic cardiac allogeneic transplant model. Read More |
| Sex as a Biological Variable: Mechanistic Insights and Clinical Relevance in Solid Organ Transplantation From Nov. 24: Biological sex affects immunity broadly, with recognized effects on the incidence and severity of autoimmune diseases, infections, and malignancies. Consequences of sex on alloimmunity and outcomes in solid organ transplantation are less well defined. Read More |
